Investment Summary

EQT Life Sciences Invests In OxThera

On December 9, 2016, growth capital firm EQT Life Sciences invested in life science company OxThera

Investment Highlights
  • This is EQT Life Sciences’ 6th transaction in the Life Science sector.
  • This is EQT Life Sciences’ 1st transaction in Sweden.

Investment Summary

Date 2016-12-09
Target OxThera
Sector Life Science
Investor(s) EQT Life Sciences
Deal Type Growth Capital

Target

OxThera

Stockholm, Sweden
OxThera is a biopharmaceutical company, uses the proceeds to complete the Oxabact development program for treatment of Primary hyperoxaluria. OxThera was founded in 2005 and is based in Stockholm, Sweden.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


DEAL STATS #
Overall 13 of 47
Sector: Life Science M&A 6 of 30
Type: Growth Capital M&A Deals 3 of 5
Country: Sweden M&A 1 of 1
Year: 2016 M&A 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-08 Vivasure Medical

Galway, Ireland

Vivasure Medical is a medical device company developing advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure Medical was founded in 2009 and is based in Galway, Ireland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-02 Imcheck Therapeutics

Marseilles, France

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Buy -